Mid
V
VTRSAI Stock Diagnostic Report
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M
Viatris reported second-quarter results for 2026 that exceeded expectations and raised its annual outlook, recording a positive development by selling the rights to its ophthalmic treatment.
View Source Article ↗AI CATALYST SCORE80 / 100Score computed by Sentinel V12
REFERENCE PRICE$17.65Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
Viatris reported revenues of $3.8 billion in Q2 2026, exceeding expectations, and secured a financial foundation to focus on its core business by selling the global rights to its ophthalmic drug 'Tyrvaya' to Harrow for up to $100 million, amidst an overall trend of improving financial health.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The company has raised its full-year guidance to reflect future growth potential, with momentum from increased efficiency and improved profitability through the sale of non-core assets.